- A new genome-wide association study of nearly 500,000 U.S. veterans of European and African genetic ancestry identified several novel, common genetic loci (gene locations) associated with dilated cardiomyopathy.
- The uncovered genetic loci were associated with dilated cardiomyopathy in heart muscle cells.
- The study’s findings have important implications for precision medicine to improve diagnosis and treatment strategies for people with dilated cardiomyopathy.
Embargoed until 4 a.m. CT/5 a.m. ET, Monday, Nov. 8, 2021
(NewMediaWire) – November 08, 2021 – DALLAS – A genome-wide association study has identified several common genetic loci (genetic locations) associated with dilated cardiomyopathy in U.S. veterans of European and African ancestry, according to preliminary research to be presented at the American Heart Association’s Scientific Sessions 2021. The meeting will be fully virtual, Saturday, November 13 through Monday, November 15, 2021, and is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide.
Dilated cardiomyopathy is a type of heart disease that occurs when the heart’s chambers become enlarged, making it harder to pump blood to the rest of the body. Approximately one-third of people with dilated cardiomyopathy inherit the condition from their biological parents, and the disease is more prevalent among people of African ancestry. Dilated cardiomyopathy worsens over time if untreated.
While the identification of relevant, common genetic variants has recently shown promise, these efforts have been limited by the availability of patients with previously diagnosed dilated cardiomyopathy.
“Numerous rare genetic mutations have been linked to dilated cardiomyopathy, yet the identification of relevant, common genetic variants has been more limited,” said Krishna G. Aragam, M.D., M.S., a cardiologist and researcher at the Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of MIT and Harvard in Boston. “In this analysis, we leveraged data from the National VA Healthcare System to study the association of common genetic variants with dilated cardiomyopathy.”
Aragam and colleagues conducted a retrospective, genome-wide association study using electronic health records from the U.S. Department of Veteran Affairs’ Million Veteran Program, a national research program including more than 825,000 former U.S. military service members since 2011 that is focused on how genes, lifestyle and military exposure may affect health and illness. Medical records through September 30, 2019, for nearly 500,000 participants in the Million Veteran Program were extracted, and the average age was 61 years, and approximately 90% were male.
The authors approximated a dilated cardiomyopathy phenotype through queries of the electronic health record, and identified over 24,000 individuals with the condition, including three-quarters of European ancestry and one-quarter of African ancestry. Genetic analysis identified 29 common genetic loci significantly associated with dilated cardiomyopathy. Notably, the uncovered loci included genes relevant to cells of the heart muscle (cardiomyocytes). The genetic risk scores were able to predict incident dilated cardiomyopathy in another dataset from the UK Biobank. These results provided strong validation of the phenotype of dilated cardiomyopathy.
Dr. Aragam added, “We were encouraged that our phenotypic construct of dilated cardiomyopathy—based predominantly on electronic health records—was supported by more than one line of genetic evidence. Our findings, therefore, highlight the potential for collaborative studies leveraging data from health care system-associated biobanks to investigate common genetic loci associated with dilated cardiomyopathy. Such efforts may rapidly advance our ability to identify the individuals at highest risk of dilated cardiomyopathy in advance, and ultimately improve their prognosis and management.”
“These researchers have found five additional locations in the human genome associated with dilated cardiomyopathy that we didn’t know about before, and there’s the potential that in the future, we could develop therapies that take advantage of one or more of these genes in order to be able to provide more targeted treatment for people who have dilated cardiomyopathy,” said American Heart Association volunteer expert Kiran Musunuru, M.D., Ph.D., M.P.H., M.L., FAHA, chair of the writing group for the Association’s 2020 scientific statement “Genetic Testing for Inherited Cardiovascular Diseases,” and professor of medicine, scientific director of the Penn Center for Inherited Cardiovascular Disease and director of Genetic and Epigenetic Origins of Disease Program at the Cardiovascular Institute at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia. “In addition, there’s also the possibility that we can use this information to better predict exactly who is at risk of getting the disease and who is not at risk. Thus, it can help us identify people who need to be monitored closely, for example, adults who may need occasional ultrasounds of the heart over the years, to look for any new sign of disease and then be able to provide treatment earlier.”
Co-authors are Mark Chaffin, M.S.; Wallace Wang, M.S.; Brian Charest, M.S., M.P.H.; J. Michael Gaziano, M.D., M.P.H.; Peter W.F. Wilson, M.D.; Lawrence S. Phillips, M.D.; Patrick Ellinor, M.D., Ph.D.; Jacob Joseph, M.D.; Yan Sun, Ph.D., M.S.; and Jennifer E. Huffman, Ph.D., M.Sc. Authors’ disclosures are listed in the abstract.
The study was funded by the Department of Veterans Affairs Office of Research and Development, Million Veteran Program Award I01-CX001737 (PI: Phillips) and the National Heart Lung and Blood Institute of the National Institutes of Health (1K08HL153937, PI: Aragam).
Statements and conclusions of studies that are presented at the American Heart Association’s scientific meetings are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
The American Heart Association’s Scientific Sessions 2021 is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care professionals worldwide. The 3-day meeting will feature more than 500 sessions focused on breakthrough cardiovascular basic, clinical and population science updates in a fully virtual experience Saturday, November 13 through Monday, November 15, 2021. Thousands of leading physicians, scientists, cardiologists, advanced practice nurses and allied health care professionals from around the world will convene virtually to participate in basic, clinical and population science presentations, discussions and curricula that can shape the future of cardiovascular science and medicine, including prevention and quality improvement. During the three-day meeting, attendees receive exclusive access to more than 4,000 original research presentations and can earn Continuing Medical Education (CME), Continuing Education (CE) or Maintenance of Certification (MOC) credits for educational sessions. Engage in Scientific Sessions 2021 on social media via #AHA21.
About the American Heart Association
The American Heart Association is a leading force for a world of longer, healthier lives. With nearly a century of lifesaving work, the Dallas-based association is dedicated to ensuring equitable health for all. We are a trustworthy source empowering people to improve their heart health, brain health and well-being. We collaborate with numerous organizations and millions of volunteers to fund innovative research, advocate for stronger public health policies, and share lifesaving resources and information. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA Expert Perspective: